Identifying mutations that cause cystic fibrosis (CF) is important for making an early, unambiguous diagnosis, which, in turn, is linked to better health and a greater life expectancy. In patients of African descent, a molecular diagnosis is often confounded by the fact that the majority of investigations undertaken to identify causative mutations have been conducted on European populations, and CF-causing mutations tend to be population specific. We undertook a survey of published data with the aim of identifying causative CF mutations in patients of African descent in the Americas. We found that 1,584 chromosomes had been tested in only 6 countries, of which 876 alleles (55.3%) still remained unidentified. There were 59 mutations identified. Of those, 41 have been shown to cause CF, 17 have no associated functional studies, and one (R117H) is of varying clinical consequence. The most common mutations identified in the patients of African descent were: DF508 (29.4% identified in the United States, Colombia, Brazil, and Venezuela); 3120 1 1G.A (8.4% identified in Brazil, the United States, and Colombia); G85E (3.8% identified in Brazil); 1811 1 1.6kbA.G (3.7% identified in Colombia); and 1342 2 1G.C (3.1% identified in the United States). The majority of the mutations identified (81.4%) have been described in just one country. Our findings indicate that there is a need to fully characterize the spectrum of CF mutations in the diaspora to improve diagnostic accuracy for these patients and facilitate treatment.
"Woe to that child which when kissed on the forehead tastes salty. He is bewitched and soon must die." (1) . This dire warning from the 1800s was about children born with cystic fibrosis (CF). In the absence of medical intervention, patients with CF were not expected to see their first birthday; in fact, life expectancy for patients with CF in 1938 was only 6 months (2) . In addition to elevated sweat chloride levels, classic CF symptomology includes chronic lung disease and pancreatic insufficiency (3) . As our understanding of the underlying cause of the disease has grown, new diagnostic and treatment strategies have been devised that have raised life expectancy for patients with CF around the world. This improvement has not been uniform: the life expectancy of patients with CF can range from 20.5 years in South Africa (4) to 49.7 years in Canada (5) .
Mutations in the CF transmembrane conductance regulator (CFTR) gene interfere with the ability of this ion channel protein to regulate the chloride balance across apical membranes. This results in a depleted airway surface liquid layer, impeding the mucociliary clearance mechanism and creating an environment in which bacteria (usually Pseudomonas aeruginosa) can establish an infection (2) .
Over time, P. aeruginosa ceases to exist solely in its planktonic form, and forms a sessile community within a protective biofilm, which is largely impervious both to antibiotics and the immune response (6) . It should be noted that respiratory complications are the leading cause of death among patients with CF (7).
More than 2,000 mutations have been identified in patients with CF around the world (8) . Causative mutations tend to be population specific, varying by both country of origin and race (9) . CF mutations have been organized into six classes based on the effect they have on the CFTR, which can range from no functional CFTR being produced (class I) to reduced amounts of functional CFTR at the cell surface (class VI) (2) . Until recently, CF treatment has focused on symptom alleviation. However, the U.S. Food and Drug Administration's (FDA) approval of Ivacaftor in 2012 marked the first application of pharmacotherapy that directly addresses the molecular cause of the disease. Ivacaftor was developed to treat G551D, a class III gating mutation. Its use has since been expanded for the treatment of additional class III mutations (2) . Further investigations are underway to identify other class-specific drugs for CF.
CF and Race
CF was historically seen as a disease that was limited to a given race, but research has since shown that CF is not ethnically linked (10) . Despite the fact that one of the earliest reports of CF in a black patient was published in 1959 (11), the notion that CF only occurs in white children has lingered. This assumption led to the majority of early investigations into the cause of CF being conducted in white populations, which may be why the countries with a mutation detection rate in excess of 95% are all European (12) .
Another consequence of this lack of data is the fact that there are more likely to be false-negative results for a patient with CF who is not white (10, 13) . This may result in a delayed diagnosis (or misdiagnosis), which can negatively impact patient health, longevity, and treatment costs (7). One study suggested that patients diagnosed after they were 6 weeks old had double the risk of developing severe pulmonary disease as they aged (14) . Delays in diagnosis have also been linked to worse pulmonary function, nutritional status, cognitive function, and premature death (7) . It has been estimated, based on CF registry data, that each patient in whom diagnosis is delayed would spend about one million euros more on treatment over their lifetime than a patient identified by a newborn screening program (15).
There have since been many reports of CF in patients of varying ethnicities, including reviews of the molecular epidemiology of CF in Africa (13) and Latin America (16) . Because members of the African diaspora could be expected to have genomes derived from admixture between Europeans and Africans, and because all populations are known to be affected by this disease, it would be reasonable to assume that CF would be a source of morbidity in the diaspora.
We defined the African diaspora as individuals of African descent in the Americas, especially the descendants of West Africans who were conscripted to work as part of the trans-Atlantic slave trade. We focused on the Americas (North, South, and Central America, and the Caribbean), as this is the region where the majority of Africans were taken. We used Google Scholar (http://scholar.google.com/) to find papers that characterized mutations in African diaspora patients. Given that identifying CF-causing mutations has become increasingly important for diagnosis and targeted pharmacotherapy, we reviewed the literature to determine the extent to which mutations have been identified in the Americas. We also wanted to determine if there were any region-specific issues facing patients with CF.
Investigations in the Diaspora
In the Americas, there were 18 papers describing the identification of mutations in patients with CF from 6 countries: the United States (17) (18) (19) (20) (21) (22) (23) (24) (25) ; Haiti (26); French Guiana (27) ; Brazil (28) (29) (30) (31) (32) (33) ; Colombia (34); and Venezuela (35) . Together, the authors of these articles assessed 1,584 CF chromosomes in members of the African diaspora, but used a variety of methods to identify mutations. None of the papers included relied solely on an unbiased sequencing approach (see Table E1 in the online supplement), and thus 876 alleles remained unidentified (55.3% of all chromosomes tested). Although the Caribbean has the highest percentage of African descendants in the general population in the Americas, there are no published records of any local attempts to identify CF-causing mutations in members of the diaspora living in this geographical region.
There were 59 mutations identified in the diaspora, of which 41 have been shown to cause CF, 17 have no associated functional studies, and 1 (R117H) is of varying clinical consequence ( Table 1) . As expected, mutations were identified in the diaspora that had previously been associated with predominantly white (such as ΔF508) or black (3120 1 1G.A, A559T) patients. When compared with mutations identified in African patients with CF (13), there was an overlap of 18 mutations, of which only I1203V has no associated functional study. Of the West African countries largely involved in the trans-Atlantic slave trade, only Senegal has any published reports of CF-causing mutations (13) , and none of these were identified in the diaspora ( Table 2 ). It is possible that the mutations in the overlap could also be present in the relevant West African populations, which could explain their presence in the Americas. There were 41 mutations found in the diaspora that have not yet been identified in African patients.
Mutations that are associated with a severe phenotype usually result in pancreatic insufficiency. The CFTR2 database (www.cftr2.org) has information on more than 66,000 patients with CF, largely from European and American CF clinics. Of the mutations identified in the diaspora, 42 were present in this database. We searched CFTR2 for each of these 42 mutations to determine how many of them were associated with pancreatic insufficiency (a marker of mutation severity) in the majority of the patients having that particular mutation in the database. Most of the mutations (92.5%) identified in the diaspora patients and included in CFTR2 are associated with pancreatic insufficiency, which indicates a severe phenotype.
The most frequent test result was an unknown mutation (U; 56.5%). The most common mutations identified in the diaspora were: DF508 (29.4% identified in the United States [17] [18] [19] [20] [21] [22] , Colombia [34] , Brazil [28] [29] [30] [31] [32] , and Venezuela [35] ); 3120 1 1G.A (8.4%; identified in Brazil [29, 31] , the United States [18, 19, 21] , and Colombia [34] ); G85E (3.8% identified in Brazil [29, 31] ); 1811 1 1.6kbA.G (3.7% identified in Colombia [34] ); and 1342 2 1G.C (3.1% identified in the United States [22] ). Most of these mutations (79.7%) have been found in just one country, which supports the idea that mutations tend to be population specific. The majority of the alleles assessed were from African Americans (764 chromosomes) or Afro-Brazilians (710 chromosomes).
There are some limitations imposed by the data. The majority of the data has been SPECIAL ARTICLE derived from Brazil and the United States. The Caribbean, where significant proportions of the population are of African descent, is grossly underrepresented. In addition, no study used an unbiased sequencing strategy that covered the entire CFTR gene, and many relied on kits that could only detect certain mutations.
There are several consequences to this. First, novel mutations could not have been identified. Second, African genomes are known to possess unparalleled genetic diversity (36) . It is therefore reasonable to assume that CF-causing mutations would be present in the diaspora that would not be included on any available genetic test. Third, commercial kits are largely based on European data (37) , which may explain the observed low mutation detection rate. Fourth, because there has not been a standard approach to identifying mutations over the 19-year span of these publications, it is possible that some of the unknown mutations may have been uncovered if all patients had been tested for all 59 mutations identified. Finally, given the population specificity of these mutations (9), having so much of the Caribbean and Latin American populations excluded from these investigations represents a gap in the literature that could negatively impact the ability of clinicians to accurately diagnose patients with CF in these regions and in the broader diaspora.
Issues Surrounding Diagnosing CF in the Diaspora
The trans-Atlantic slave trade was responsible for the movement of an estimated 12 million people, largely from West Africa, to the Americas to work as slaves on plantations. This forced exodus from the mother continent altered the course of history in many ways, including bringing African genomes to the West in large numbers. It should be possible to trace the ancestry of patients with CF in the diaspora using the mutations they carry. However, the molecular epidemiology of CF in Africa remains largely unexplored. The majority of the work on the continent has been done in northern and southern African states (13) , which precludes using the data to speculate about the ancestry of patients with CF in the diaspora. For instance, 3120 1 1G.A has been identified in Table 2 ). There are no obvious historical migratory patterns linking these eastern and western countries. Although available data cannot be used to trace ancestry, they do highlight that patients with CF of African descent are at a distinct diagnostic disadvantage that negatively affects their prognosis.
Almost 30 years after the identification of the responsible gene, the molecular diagnosis of patients with CF continues to be inadequate because of the sheer diversity of causative mutations (more than 2,000 variants have been identified in patients with CF around the world [8] ) and their population-specific nature (9). This is further compounded when working in a clinical setting that serves a genetically diverse population, such as might be found among Africans and members of the African diaspora. Admixture also contributes an additional layer of complexity. Although African genomes are known to be highly diverse (36) , they also tend to be understudied, which is the case with CF, especially because it was assumed that this disease could only affect those of European or Caucasian descent (37) .
If we examine the data from Brazil, we also see that, when a set of known mutations is used to identify patients with CF, white patients have a significantly higher mutation detection rate (80.7%) than black individuals (21.1%) (31) . This may be because the majority of the mutations on the panel had previously been identified in Europeans. The diversity resident in African genomes is likely to play a role here. These findings underscore the need to investigate the mutations relevant in the diaspora to reduce the likelihood that patients with CF will receive a delayed diagnosis or be misdiagnosed.
Further assessment of the data also revealed that 48 of the 59 mutations (81%) had been identified in only one country (Table 1) . This is not unexpected, because causative mutations have repeatedly been demonstrated to exhibit population specificity. This does mean that genetic tests need to be developed for a given population instead of taking a one-test-fitsall approach. There was only one country (the United States) where the most common test result was not an unknown mutation (Table E1) . As is the global trend, a few mutations in this data set account for the majority of the alleles tested, whereas the majority of mutations identified occurred at frequencies below 3% ( Table 1) .
Misdiagnosis of patients with CF of African descent is possible because it is a relatively rare disease, and other phenocopic illnesses are more likely to be perceived as the cause of the patient's symptoms (31, 38) . If the attending physician is unaware that CF is not an ethnically linked disease, this also increases the likelihood that members of the diaspora may be misdiagnosed (13, 38) . The phenotypes of patients with CF exist along a continuum (37) in which a single test may not be able to lead to a conclusive diagnosis. For instance, a patient with CF may have a borderline sweat test result, normal or intermediate fecal elastase result, and no or only one mutation identified by the genetic test in use in his or This mutation has no associated functional study.
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her country. It may therefore be difficult for a physician to diagnose CF, especially for patients who do not present with the classic symptoms. Sequencing of these patients' CFTR may be helpful in resolving their diagnosis (39) . Currently, the highest mutation detection rates are among European populations (about 100% in Finland, 80% in Europe, 60% in South Asia, 40% in the Americas, and about 45% in Africa) (37) . Using the panel recommended by the American College of Medical Genetics (40), only about 30% of carriers of CF in the Americas (an admixed group from North, South, and Central America) are detected (37) . This percentage increases to 40% (37) if all of the CFTR2 mutations (41) are used to screen these individuals. Additional research is definitely needed to identify the set of mutations that would raise the detection rate above 95% in the diaspora. If the American College of Medical Genetics panel (40) had been used to screen this diaspora cohort, 65.3% of the mutations would have remained unidentified, which raises the question: should we continue to use genetic screening for diagnosis, especially in non-white populations?
Using next-generation sequencing (NGS) to diagnose CF outperforms conventional genetic testing in terms of mutation detection rates (42) and positive predictive value (43) . One approach combined sequencing 182 of the 189 kb that constitutes CFTR with a bioinformatics pipeline that was able to identify singlenucleotide polymorphisms, indels, and gross rearrangements to achieve a diagnostic rate of 98.9%. The authors estimated that a traditional multitier diagnostic algorithm could cost €400 and take 2-3 months, whereas their strategy cost about €200 and was completed in 14 days (44) . A more recent paper covered significantly fewer bases using NGS (16.5 kb as opposed to 182 kb), but the associated bioinformatics pipeline had a positive predictive value of 100% and identified single-nucleotide polymorphisms, indels, and large deletions. This protocol was estimated to cost $15 per sample if 95 samples were sequenced per run, and the analysis would be complete within 3 days (45) .
It may therefore be time to consider a similar approach to diagnosing patients with CF, especially those that are not of European descent, who are underserved by current genetic tests. It should also be borne in mind that, with the advent of Ivacaftor (and with other class-specific drugs being developed [2, 46] ), the ability to resolve the molecular status of patients with CF has become an important precursor for targeted pharmacotherapy.
Reducing the length of the diagnostic odyssey in these patient groups will have a positive impact on morbidity and mortality. Patients with CF who were identified via newborn screening had better height and age-for-weight Z scores during the first 6 months postpartum when compared with those diagnosed based on their symptoms (and thus diagnosed later), a gap that persisted throughout the course of the study. This effect was most pronounced with height-for-age, suggesting that delayed diagnosis may be associated with permanent stunting (47) . Delays in diagnosis also result in prolonged vitamin deficiency, which can affect cognition. Patients with CF with a-tocopherol deficiency at diagnosis were stratified into those identified by screening and those identified symptomatically. When these patients were given a test of cognitive skills, the delayed diagnosis group had cognitive skills index scores 12.5 points lower than their screened counterparts (7) . Approximately 50% of symptomatically diagnosed patients had potentially irreversible lung damage by age 2 years as opposed to 29% of patients who had been diagnosed via newborn screening. Screened patients had better forced expiratory volume in 1 second percentage scores than those diagnosed later, but this difference shrank with time until the better predictor of lung function was P. aeruginosa infection (7, 47) .
The Way Forward
Based on the available data, patients with CF in the African diaspora are at a distinct disadvantage when compared with their European counterparts (11, 37) . Global data suggest that the number of CF-causing mutations in patients of European descent may be approaching a plateau. Conversely, there seems to be many more mutations yet to be identified in the CFTR of patients of African descent. Patients with CF in the diaspora face two major obstacles to an early and accurate diagnosis. First, they have a relatively rare disease, which occurs at a lower frequency in their population group than in those of European descent (10) . This may increase their chances of being misdiagnosed, especially in areas where there are more rampant phenocopic illnesses, such as malnutrition, viral or parasitic infection, or tuberculosis (11, 38) . Second, there is not enough information available about the mutations present in these subpopulations for the design of suitable genetic tests (12, 37) . This also increases the probability that these patients may be misdiagnosed, particularly if they don't present with the classic triad of CF symptoms or if they have milder forms of the disease.
At the very least, it would be useful to sequence the CFTR in individuals in the diaspora suspected of having CF (the World Health Organization [WHO] recommends at least 50-100 patients [12] ). Because causative mutations tend to be population specific (9) , and given the diversity known to reside in African genomes (36) , it would be reasonable to assume that several mutations would be identified by this survey, and that some of them may well be novel.
This information could be used to design genetic tests that are tailored to each subpopulation in the diaspora, which would raise the mutation detection rate. These tests could serve an important role in reducing the false-negative rates among diaspora patients, and could assist in reducing the length of time required for these patients to receive an accurate diagnosis. As has been repeatedly demonstrated, early diagnosis is correlated with better prognosis and lower lifetime treatment costs (7, 14, 15) . Being aware of which mutations each patient carries also opens up new therapeutic options as more class-specific drugs are developed (2, 46) . As recent literature suggests (44, 45) , sequencing has several advantages over panel tests, and may be a cheaper and faster way to arrive at a diagnosis.
There may be objections raised regarding changing current diagnostic algorithms, but this must be considered in light of the cost of doing nothing. In Latin America, for example, the mean age of diagnosis for CF is 3.7 years, whereas the mean age at which patients are first seen in clinics is 4.5 years (48) . This delayed diagnosis and associated lack of access to early appropriate treatment is known to SPECIAL ARTICLE Special Articlehave a negative impact on prognosis and quality of life (7, 14) . The median age at death is 6.68 years, and only 10% of patients survive to adulthood (48) , which is in stark contrast to Canada, where CF life expectancy is almost 50 years (5) . Approximately 25% of these Latin American patients had normal lung function (forced expiratory volume in 1 second percentage above 80%), and it was reported that 80% had microbial colonization of their airways (48) .
These dire health statistics concur with the WHO statement that "the societal costs of inaction in genetics, measured in terms of avoidable human suffering and the burden on public health are very high." The WHO therefore suggested that countries "recognize that there are approaches to their [genetic disease] management and prevention that can significantly reduce their burden in a cost-effective manner" (49) . Improving diagnostic accuracy and helping patients access appropriate care is one way to improve the health of patients with CF in the diaspora.
Conclusions
In the clinical setting, it is important not to exclude CF as a diagnosis based on race. When dealing with genetically diverse populations, sequencing is needed to identify relevant mutations that are absent from commercially available genetic tests (37, 39) . This process would generate data that could resolve the patient's CF status, be useful in designing a genetic test with a higher mutation detection rate, and determine if a patient may benefit from one of the class-specific drugs that have recently become available (2, 46) . Alternatively, given recent data that suggest that pairing NGS with an appropriate bioinformatics pipeline could significantly reduce both the time and cost involved in CF diagnosis (44, 45) , it may be time to begin switching to sequencing as the primary diagnostic method. This should have particular utility in diverse populations, such as are found in Africa and its diaspora, which have suffered from the inherent European bias in the current genetic tests. If this approach is taken within the context of a larger public health policy, it could lower the age at diagnosis for patients with CF, which should both decrease morbidity and raise life expectancy (13) . Critically, it would gradually eliminate the immediate diagnostic disadvantage faced by non-white patients with CF. n
